<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>X-linked ichthyosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">X-linked ichthyosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">X-linked ichthyosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H98140592"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>X-linked ichthyosis (XLI; MIM #308100), also called steroid sulfatase (STS) deficiency, is caused by deletions or pathogenic variants in the <em>STS</em> gene (encoding the STS enzyme) and is generally considered nonsyndromic [<a href="#rid1">1</a>].</p><p>The disease presents at birth or in early infancy with dry skin and a tendency to form scales on the extremities and trunk. Along with ichthyosis vulgaris, the skin phenotype of XLI tends to be milder than most other hereditary forms of ichthyosis.</p><p>This topic will review the clinical features, diagnosis, and management of XLI. An overview of syndromic and nonsyndromic ichthyoses  (<a class="graphic graphic_table graphicRef90504" href="/z/d/graphic/90504.html" rel="external">table 1</a>) and selected subtypes of inherited ichthyoses are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a>.)</p><p></p><p class="headingAnchor" id="H98140598"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Recessive XLI is the second most frequent ichthyosis after ichthyosis vulgaris. It is reported worldwide in all ethnic groups and almost exclusively affects males. XLI prevalence ranges from 1 in 1300 to 1 in 9000 male births [<a href="#rid2">2-5</a>].</p><p>Since the prevalence of steroid sulfatase (STS) deficiency detected by routine prenatal biochemical screening is approximately 1 in 1500 males and the rate detected by clinical diagnosis is significantly lower (1 in 3000 to 1 in 6000), STS deficiency may not cause clinically identifiable disease in a significant number of cases [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H98140604"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H3508532507"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The majority of cases of XLI are caused by complete deletion of the steroid sulfatase gene (<em>STS</em>) on chromosome Xp22.31 [<a href="#rid7">7,8</a>]. Other cases result from partial deletion or point mutations of <em>STS </em>[<a href="#rid9">9,10</a>]<em>.</em> These pathogenic variants of the <em>STS</em> gene cause complete loss of STS enzyme activity.</p><p>In a Dutch cohort of 109 males with suspected XLI, 71 (65 percent) had a molecularly confirmed pathogenic variant of <em>STS </em>[<a href="#rid11">11</a>]. Of these, 57 (80 percent) had a contiguous hemizygous deletion of the entire <em>STS</em> gene and at least part of the flanking <em>PUDP</em> sequence. The rest were point mutations or smaller copy number errors (deletions, duplications) that disrupted only the <em>STS</em> gene.</p><p>Due to the location of the <em>STS</em> gene within a small region on the distal half of the short arm of the X chromosome that escapes X-inactivation (lyonization), recessive XLI almost exclusively affects males, and females do not show mosaic skin lesions [<a href="#rid12">12,13</a>]. Affected males usually inherit the X chromosome bearing a deleted or mutated gene from their carrier mother, who is clinically unaffected. Rare de novo cases have been reported [<a href="#rid14">14,15</a>]. In 5 to 8 percent of cases, a larger deletion includes additional genes adjacent to <em>STS</em>,<em> </em>resulting in a number of contiguous gene syndromes depending on the size of the deletion [<a href="#rid16">16,17</a>]. (See <a class="local">'Contiguous gene syndromes'</a> below.)</p><p>Of note, some patients with XLI also carry concomitant variants in the filaggrin gene (<em>FLG</em>), which result in a more severe phenotype as well as in associated findings of atopic dermatitis [<a href="#rid11">11,18</a>].</p><p class="headingAnchor" id="H879745233"><span class="h2">Protein function</span><span class="headingEndMark"> — </span>STS is a 65 kDa microsomal enzyme that localizes to the endoplasmic reticulum, Golgi apparatus, and endosomal membranes, including coated pits of placenta and several other tissues. STS hydrolyzes alkyl steroid sulfates (eg, dehydroepiandrosterone sulfate [DHEAS], aryl steroid sulfates) to their unconjugated (unsulfated) forms [<a href="#rid19">19,20</a>]. In the epidermis, STS activity is high in the granular layer and persists in the stratum corneum, where it contributes to the production of cholesterol available to form the extracellular lamellar bilayers and participates in the regulation of permeability barrier function and desquamation. Deficient STS activity leads to accumulation of cholesterol sulfate in the stratum corneum, which inhibits proteases that normally degrade corneodesmosomes [<a href="#rid21">21</a>]. Impaired desquamation is associated with increased corneocyte cohesion, retention hyperkeratosis, and impaired skin permeability [<a href="#rid19">19,22-24</a>].</p><p class="headingAnchor" id="H160904331"><span class="h2">Effects of fetal STS deficiency on maternal estriol levels during pregnancy</span><span class="headingEndMark"> — </span>In women pregnant with an affected fetus, placental STS deficiency causes low maternal urinary and blood unconjugated estriol levels due to inadequate deconjugation of DHEAS, which is necessary for estrogen synthesis [<a href="#rid19">19</a>]. Normally, the STS enzyme synthesizes estriol in the placenta, which circulates in maternal blood. When a fetus is affected with XLI (STS deficiency), the mother, correspondingly, has abnormally low levels of unconjugated serum estriol (uE3) during pregnancy. If a mother carrying an XLI-affected fetus is offered and pursues a second-trimester screening test for Down syndrome, which relies on levels of serum analytes including uE3, the screen will be abnormal and not useful for detection of Down syndrome. (See  <a class="medical medical_review" href="/z/d/html/414.html" rel="external">"Maternal serum marker screening for Down syndrome: Levels and laboratory issues"</a>.)</p><p class="headingAnchor" id="H2791540288"><span class="h2">Effects of STS deficiency on brain development</span><span class="headingEndMark"> — </span>STS is expressed in the brain both during development and normal function [<a href="#rid6">6</a>]. Several studies support that impaired STS function may affect neurodevelopment and brain function [<a href="#rid6">6,21,25</a>]. Neurocognitive differences present in affected males, who carry pathogenic point mutations and small deletions, as well as in those with deletions of the entire <em>STS</em> gene and a small number of surrounding genes, which supports that behavioral changes are caused by reduced STS activity itself (rather than deletion of adjacent genes as previously suspected) [<a href="#rid21">21</a>]. Affected males have an increased tendency toward behaviors such as inattention, impulsivity, mood disorders, and autism-related traits [<a href="#rid6">6</a>]. Data suggest that female carriers also have an increased risk of attention deficit hyperactivity disorder (ADHD)-related behaviors, similar to that of affected males, due to reduced STS activity and expression [<a href="#rid6">6</a>].</p><p>Atrial fibrillation is reported at an increased rate in adult males with XLI [<a href="#rid26">26</a>]. The mechanism is not known with certainty, though a relationship with circulating DHEAS levels is suspected.</p><p class="headingAnchor" id="H2986799379"><span class="h1">PERINATAL MANIFESTATIONS OF STS DEFICIENCY</span><span class="headingEndMark"> — </span>Steroid sulfatase (STS) is a key enzyme in the biosynthesis of estriol in the human placenta. A placental STS deficiency, which occurs in pregnancies of XLI fetuses, causes abnormally low levels of serum estriol in mothers during pregnancy. Recessive XLI may be diagnosed prenatally as an incidental finding in pregnant women undergoing a screening blood test for Down syndrome, which includes alpha-fetoprotein (AFP), unconjugated estriol, human chorionic gonadotropin, and inhibin A. (See  <a class="medical medical_review" href="/z/d/html/426.html" rel="external">"Down syndrome: Overview of prenatal screening"</a>.)</p><p>The impact of STS deficiency on pregnancy and delivery is unclear. Some authors report a delayed or prolonged labor (&gt;20 hours) and reduced response to <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a>, especially in primiparous females [<a href="#rid27">27,28</a>]. However, no special interventions are recommended unless there are specific obstetric indications [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H98140610"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In addition to ichthyosis, steroid sulfatase (STS) deficiency may be associated with several extracutaneous manifestations, including corneal opacities; cryptorchidism; and less commonly, neurologic, cognitive, and developmental abnormalities [<a href="#rid1">1,30,31</a>]. Increased risk of atrial fibrillation/flutter has been reported in affected adult males [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H98140622"><span class="h2">Cutaneous features</span><span class="headingEndMark"> — </span>The age at presentation is variable. The cutaneous features of XLI may appear at birth [<a href="#rid32">32</a>] or in the first few weeks of life with mild, diffuse scaling  (<a class="graphic graphic_picture graphicRef103928 graphicRef103927 graphicRef103929 graphicRef103930" href="/z/d/graphic/103928.html" rel="external">picture 1A-D</a>) and gradually develop over the following months. A presentation with a collodion membrane at birth ("collodion baby") is unusual in XLI, and most parents/caregivers do not describe noticeable skin scale or dryness at birth.</p><p>Over time, the mild desquamation may be replaced by larger, polygonal, translucent scales  (<a class="graphic graphic_picture graphicRef66723 graphicRef90658" href="/z/d/graphic/66723.html" rel="external">picture 2A-B</a>) [<a href="#rid27">27</a>]. The scales may become plate like and adherent with a brownish color and particularly involve the anterior aspect of the lower extremities. The lack of involvement in flexural areas, such as the popliteal  (<a class="graphic graphic_picture graphicRef103931" href="/z/d/graphic/103931.html" rel="external">picture 3</a>) and antecubital  (<a class="graphic graphic_picture graphicRef103932" href="/z/d/graphic/103932.html" rel="external">picture 4</a>) fossae, has traditionally been considered a distinctive feature of XLI. However, in a series of 30 patients with XLI, one-third had flexural involvement [<a href="#rid21">21</a>]. Palms, soles, and the central face are often spared. During childhood, the scalp, preauricular areas, and neck may be involved ("dirty neck" appearance) [<a href="#rid33">33</a>].</p><p>The scales tend to increase throughout childhood and then stabilize after adolescence with little subsequent change. In some patients, a concurrent ichthyosis vulgaris and/or atopic dermatitis may exacerbate the symptoms [<a href="#rid34">34-36</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Pruritus is generally less severe than in other forms of ichthyosis [<a href="#rid21">21,37</a>]. The desquamation improves during the summer months and is worsened by dry and cold weather [<a href="#rid33">33,38</a>]. Correspondingly, pruritus is more likely in a cold environment compared with a hot environment [<a href="#rid37">37</a>].</p><p>Hypohidrosis is associated with many forms of ichthyosis and has been reported in 19 percent of patients with XLI [<a href="#rid21">21</a>].</p><p>Clinically affected individuals with XLI have an increased risk of having associated atopic dermatitis. A Spanish study identified atopic dermatitis as a comorbidity in 23 percent of individuals affected by XLI [<a href="#rid25">25</a>]. Individuals who also have mutations in the filaggrin gene, a risk factor for atopic dermatitis, may have a more severe presentation of XLI and more skin infections [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H59463924"><span class="h2">Extracutaneous features</span></p><p class="headingAnchor" id="H98140628"><span class="h3">Ocular</span><span class="headingEndMark"> — </span>Harmless "punctate corneal opacities" are the most characteristic eye finding, present in up to 50 percent of affected males and 25 percent of carrier females [<a href="#rid39">39</a>]. The appearance is described as fine, hazy or "flour-like," comma-shaped dots in the cornea, anterior to Descemet's membrane and best visualized using a slit lamp  (<a class="graphic graphic_picture graphicRef103934" href="/z/d/graphic/103934.html" rel="external">picture 5</a>) [<a href="#rid34">34</a>]. Increasingly, multimodal high-resolution techniques (eg, in vivo confocal microscopy, optical coherence tomography) are used to visualize the anterior segment and have been reported to be useful as early as childhood [<a href="#rid40">40,41</a>]. These punctate corneal opacities are usually asymptomatic and can only rarely cause recurrent corneal erosions [<a href="#rid1">1,39</a>].</p><p class="headingAnchor" id="H98140634"><span class="h3">Genitourinary</span><span class="headingEndMark"> — </span>Cryptorchidism is described in up to 20 percent of affected male children [<a href="#rid1">1</a>]. A Spanish study of 30 patients found that 10 percent of affected male children required orchiopexy. Despite cryptorchidism, affected males have normal sexual development, testosterone levels, and fertility [<a href="#rid1">1</a>]. Of particular concern to patients and families is a possible association of recessive XLI with testicular germ cell cancer independent of cryptorchidism. However, the data to support this association are weak, with only a few cases reported in the literature [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/87856.html" rel="external">"Undescended testes (cryptorchidism) in children: Management"</a>.)</p><p>There are a few case reports of nephrotic syndrome associated with recessive XLI [<a href="#rid44">44-47</a>]. However, a true association has not been proven.</p><p class="headingAnchor" id="H914668706"><span class="h3">Cardiac</span><span class="headingEndMark"> — </span>In a large UK Biobank study of males aged 40 to 69 years, atrial fibrillation or flutter was reported in 10.5 percent of individuals with the <em>STS</em> deletion versus 2.7 percent in male controls [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H98140646"><span class="h3">Cognitive and behavioral</span><span class="headingEndMark"> — </span>Male children with recessive XLI have a higher rate of cognitive and behavioral disorders, especially attention deficit hyperactivity disorder (ADHD), compared with nonaffected children in the same age range [<a href="#rid21">21,32,48</a>]. Mood disorders, anxiety, and depression are also more prevalent in affected males and carrier females compared with the general population. In a study of 25 male children with recessive XLI, 10 fulfilled the criteria for ADHD (especially the inattentive subtype), and five fulfilled the criteria for an autistic spectrum disorder or related language/communication difficulty [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/627.html" rel="external">"Autism spectrum disorder in children and adolescents: Clinical features"</a>.)</p><p>In another study of patients from 25 families, 30 percent were affected with ADHD. Despite this well-supported association of XLI and ADHD, a study revealed no difference in highest academic level achieved between <em>STS</em> deletion carriers aged 40 to 69 years (male or female) and controls [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H2017807611"><span class="h3">Neurologic</span><span class="headingEndMark"> — </span>Epilepsy was overrepresented (13 percent) in a group of 30 clinically diagnosed male children in Spain [<a href="#rid21">21</a>]. Increased seizure risk in XLI is further supported in a report of three affected male children with self-limited focal epilepsy of childhood and an Xp22.31 <em>STS</em> deletion that includes <em>STS</em>, <em>PUDP</em>, and <em>MIR4767</em> [<a href="#rid49">49</a>]. These findings suggest that <em>STS</em> pathogenic variants may be an independent risk factor for seizures [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2918273919"><span class="h1">CLINICAL FINDINGS IN FEMALE CARRIERS</span><span class="headingEndMark"> — </span>Corneal opacities and increased risk of attention deficit hyperactivity disorder (ADHD)-related behaviors have been described in female carriers of <em>STS</em> variants [<a href="#rid6">6,26,39</a>].</p><p class="headingAnchor" id="H98140652"><span class="h1">CONTIGUOUS GENE SYNDROMES</span><span class="headingEndMark"> — </span>Abnormal recombination of homologous sequences in the <em>STS</em> chromosomal region may cause terminal or interstitial deletions that include adjacent genes, resulting in complicated clinical phenotypes [<a href="#rid50">50</a>]. In addition to ichthyosis, abnormalities reported in male patients with recessive XLI and contiguous gene syndromes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive disability [<a href="#rid51">51,52</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypogonadotropic hypogonadism and anosmia (Kallmann syndrome, MIM #308700), caused by a large deletion of the short arm of the X chromosome proximal to and including the <em>STS</em> gene [<a href="#rid53">53</a>] (see  <a class="medical medical_review" href="/z/d/html/7465.html" rel="external">"Isolated gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chondrodysplasia punctata, nasal hypoplasia, and developmental delay [<a href="#rid54">54-56</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Developmental delay and short stature [<a href="#rid57">57</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anosmia, hypogonadotropic hypogonadism, nystagmus, and decreased visual acuity [<a href="#rid58">58</a>]</p><p></p><p class="headingAnchor" id="H98140664"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H59463696"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>The diagnosis of recessive XLI is suspected in an infant based upon one or more of the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of unusually dry skin in the first weeks of life that evolves to polygonal, brownish scales</p><p class="bulletIndent1"><span class="glyph">●</span>Birth history characterized by a prolonged labor (&gt;20 hours) and/or nonelective cesarean section</p><p class="bulletIndent1"><span class="glyph">●</span>Maternal finding of low serum estriol in the second trimester of pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of scaly skin affecting the male relatives of the mother</p><p></p><p class="headingAnchor" id="H2404334037"><span class="h2">Diagnosis confirmation</span><span class="headingEndMark"> — </span>The diagnosis of recessive XLI can be confirmed by biochemical techniques demonstrating absent steroid sulfatase (STS) enzyme activity or by molecular techniques demonstrating a deletion or mutation of the <em>STS</em> gene. Some authors advocate for a multispecialty approach in assessment of children with XLI to include assessment for the presence of neuropsychiatric signs [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H98140670"><span class="h3">Biochemical diagnosis</span><span class="headingEndMark"> — </span>The demonstration of reduced STS activity in cultured fibroblasts has the highest sensitivity because it detects cases caused by gene deletions as well as those caused by mutations. Fibroblasts can be cultured from skin biopsy using a standard technique. Typically, a 4 mm punch biopsy from a convenient area of the skin (eg, under the upper arm) is placed in a sterile container with standard culture media (<strong>not</strong> formalin) and sent to a laboratory that performs fibroblast culture. A request for STS enzyme activity testing should accompany the specimen.</p><p class="headingAnchor" id="H98140676"><span class="h3">Molecular diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of recessive XLI can be confirmed by a chromosomal microarray (CMA) test of peripheral blood. Using CMA, the <em>STS</em> region of the X chromosome (Xp22.3) can be examined for a microdeletion. (See  <a class="medical medical_review" href="/z/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Fluorescence in situ hybridization'</a>.)</p><p>CMA is a powerful genetic test that interrogates the entire genome for small deletions and copy number variants. CMA is used in obstetrics for certain situations, such as fetal congenital anomalies, and in the postnatal setting in children with multiple congenital anomalies not explained by a specific syndrome. (See  <a class="medical medical_review" href="/z/d/html/16683.html" rel="external">"Prenatal diagnosis of chromosomal imbalance: Chromosomal microarray"</a>.)</p><p>CMA may detect recessive XLI prenatally and is also useful for excluding an associated contiguous gene syndrome. Similarly, in patients who present with suspected XLI and congenital anomalies, CMA and genetic consultation may be helpful for an accurate diagnosis.</p><p>However, CMA cannot detect the minority of XLI cases caused by point mutations in <em>STS</em> or very small deletions. In suspected cases in which CMA is negative for an <em>STS</em> deletion, deoxyribonucleic acid (DNA) sequencing for point mutations in <em>STS</em> and small deletions can be performed.</p><p class="headingAnchor" id="H3679751837"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>A skin biopsy is generally not helpful for the diagnosis of XLI because the histologic features of XLI may be nonspecific, with a wide range of changes in the stratum corneum and granular layer reported. For example, the stratum corneum may appear normal or have thick hyperkeratosis  (<a class="graphic graphic_picture graphicRef104127" href="/z/d/graphic/104127.html" rel="external">picture 6</a>) [<a href="#rid1">1</a>]. The granular layer may appear normal  (<a class="graphic graphic_picture graphicRef104128" href="/z/d/graphic/104128.html" rel="external">picture 7</a>) [<a href="#rid59">59</a>], diminished [<a href="#rid19">19</a>], or absent  (<a class="graphic graphic_picture graphicRef104129" href="/z/d/graphic/104129.html" rel="external">picture 8</a>) [<a href="#rid59">59</a>]. In contrast with early reports of a normal to slightly thickened granular layer in XLI, a review of slides from eight patients found that the granular layer was generally normal or thinned [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H59464413"><span class="h1">PRENATAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Since the mothers of XLI-affected fetuses have abnormally low levels of serum estriol during pregnancy, the diagnosis is sometimes made prenatally in women who undergo a screening blood test for Down syndrome in the second trimester of pregnancy, which includes the measurement of unconjugated estriol. (See <a class="local">'Perinatal manifestations of STS deficiency'</a> above.)</p><p>When the diagnosis of STS deficiency is made prenatally, further evaluation to exclude a contiguous gene syndrome using chromosomal microarray (CMA) is recommended [<a href="#rid16">16</a>]. (See <a class="local">'Molecular diagnosis'</a> above.)</p><p class="headingAnchor" id="H59464077"><span class="h1">CARRIER DETECTION</span><span class="headingEndMark"> — </span>Measurement of steroid sulfatase (STS) enzyme activity in fibroblast culture is not useful to detect carrier females. Biochemical assay of cultured fibroblasts detects complete absence or extremely low STS activity and considers a broad range of STS activity to be normal. Since female carriers have residual activity from their normal X chromosome, an assay result from a carrier female is typically not different enough from normal to distinguish carrier status.</p><p>If an affected male is identified using chromosomal microarray (CMA), then less expensive and more specific DNA sequencing or fluorescence in situ hybridization (FISH) testing are useful to test the carrier status of female family members and male relatives. (See <a class="local">'Molecular diagnosis'</a> above.)</p><p>Genetic consultation is useful for families to understand the testing strategy and implications of the findings. (See <a class="local">'Genetic counseling'</a> below.)</p><p class="headingAnchor" id="H98140688"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of XLI includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ichthyosis vulgaris</strong> – In contrast to XLI, the skin in ichthyosis vulgaris is likely to lack the translucent, polygonal scale. Palmar hyperlinearity is characteristic of ichthyosis vulgaris but is usually absent in XLI  (<a class="graphic graphic_picture graphicRef90481" href="/z/d/graphic/90481.html" rel="external">picture 9</a>) [<a href="#rid21">21</a>]. On histology, the granular layer is absent in ichthyosis vulgaris but is usually normal or thinned in XLI. (See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'Ichthyosis vulgaris'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lamellar ichthyosis and congenital ichthyosiform erythroderma</strong> – Lamellar ichthyosis is more severe than XLI and typically presents at birth with a collodion membrane  (<a class="graphic graphic_picture graphicRef62827" href="/z/d/graphic/62827.html" rel="external">picture 10</a>) and later with large, plate-like scales that are most prominent on the trunk and lower extremities  (<a class="graphic graphic_picture graphicRef128200" href="/z/d/graphic/128200.html" rel="external">picture 11</a>). (See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'Lamellar ichthyosis and congenital ichthyosiform erythroderma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis</strong> – In infants and young children, atopic dermatitis typically presents with dry skin; pruritus; and red, scaly, or weeping lesions on the extensor surfaces and cheeks or scalp  (<a class="graphic graphic_picture graphicRef77457 graphicRef56461 graphicRef77386" href="/z/d/graphic/77457.html" rel="external">picture 12A-C</a>). Histology shows spongiosis (epidermal edema) and a lymphohistiocytic infiltrate in the dermis. In contrast to atopic dermatitis, XLI is not associated with inflammation, vesiculation, or pruritus. However, atopic dermatitis may rarely be present concurrently with XLI. Individuals with XLI have a heightened risk of atopic dermatitis, and the two conditions may occur together. (See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H98140694"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H58479426"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>There is no definitive cure for recessive XLI. Many authors report mild forms diagnosed prenatally or incidentally that may not come to clinical attention based on skin features. The disease rarely interferes with the activities of daily living, and mild forms may not require treatment [<a href="#rid1">1</a>]. However, some patients with XLI experience a significantly reduced quality of life due to self-consciousness and social embarrassment [<a href="#rid61">61-63</a>]. These patients may need lifelong treatment to control scaling and skin dryness and improve their skin appearance.</p><p>Educating parents, caregivers, and patients about the importance of daily bathing and regular, frequent application of emollients is an essential part of the management of XLI. (See <a class="local">'Control of scaling and dryness'</a> below.)</p><p>It is also essential to guide the patient in the choice of cosmetically acceptable creams and lotions to improve adherence to treatment [<a href="#rid64">64</a>]. An excellent resource for patients, parents, and caregivers with information on skin care can be found on the website of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=15472" target="_blank">Foundation for Ichthyosis and Related Skin Types (FIRST)</a>.</p><p class="headingAnchor" id="H403536567"><span class="h2">Overheating</span><span class="headingEndMark"> — </span>In some individuals, the skin is dry and thick enough to impede normal function of the sweat glands by mechanically blocking them. These patients may have a tendency to become overheated, especially in direct sunlight [<a href="#rid1">1</a>]. One of the first signs of overheating is increased redness of the skin. Ready access to a cool environment or water (including sprays or cooling vests), if needed, is recommended.</p><p>Affected individuals usually learn over time what they can or cannot tolerate, and overheating rarely causes medical problems.</p><p class="headingAnchor" id="H98140700"><span class="h2">Control of scaling and dryness</span><span class="headingEndMark"> — </span>Treatment of recessive XLI is directed at removing scales, reducing skin dryness, and improving skin appearance without causing excessive irritation. It involves regular bathing and use of emollients and keratolytics.</p><p class="headingAnchor" id="H1114713208"><span class="h3">Bathing and moisturizing</span><span class="headingEndMark"> — </span>Daily bathtub soaks in water or long showers with gentle removal of scale using a roughly textured sponge are helpful. The addition of baking soda or lubricating bath oils to bath water may be helpful [<a href="#rid65">65</a>]. Moisturizing creams or ointments should be applied immediately after bathing, while the skin is still damp. Useful moisturizers typically contain oils alone (eg, petroleum jelly) or in combination with humectants (eg, <a class="drug drug_general" data-topicid="10267" href="/z/d/drug information/10267.html" rel="external">sodium lactate</a>, low-concentration urea, propylene glycol).</p><p>In infants and young children, daily baths followed by the application of emollients is usually sufficient to remove scales. Increasing the environmental humidity is also helpful.</p><p class="headingAnchor" id="H2333708885"><span class="h3">Keratolytics</span><span class="headingEndMark"> — </span>Topical keratolytic agents are first-line treatment for reducing scale in older children and adults with XLI. Potential irritation and stinging in children, especially prior to school age, limits use and requires monitoring and dose adjustment when needed. (See  <a class="medical medical_review" href="/z/d/html/128456.html" rel="external">"Inherited ichthyosis: Overview of management", section on 'Topical keratolytic agents'</a>.)</p><p>Topical keratolytic preparations available on the market usually contain:</p><p class="bulletIndent1"><span class="glyph">●</span>5% to 12% lactic acid</p><p class="bulletIndent1"><span class="glyph">●</span>2% to 10% urea</p><p class="bulletIndent1"><span class="glyph">●</span>5% to 15% glycolic acid</p><p class="bulletIndent1"><span class="glyph">●</span>10% to 25% propylene glycol</p><p class="bulletIndent1"><span class="glyph">●</span>3% to 6% salicylic acid</p><p></p><p>Topical keratolytics should <strong>not</strong> be used in infants and young children because of the high risk of toxicity due to systemic absorption [<a href="#rid66">66-68</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Keratolytic preparations should be applied up to once or twice daily in a thin layer to the affected skin. An excessive concentration of keratolytic agents may cause skin irritation, pain, and excess peeling. As a general rule, concentration of keratolytic creams may be increased in a "start low, go slow," stepwise fashion, such as starting once per week in a small area to avoid burning and irritation. Patients with an unsatisfactory response to single keratolytics may benefit from using ointments containing a combination of keratolytics, such as 5% lactic acid with 10% urea or 2% salicylic acid with 20% urea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The evidence on the efficacy of keratolytics for the treatment of ichthyosis is limited to a few low-quality, randomized trials and observational studies, and their use is mainly based upon clinical experience and patient preference. In one study, 60 children with mild to moderate types of ichthyosis treated one side of the most severely affected extremity with a 10% urea cream and the contralateral side with vehicle for eight weeks [<a href="#rid69">69</a>]. A very good or good investigator-assessed improvement was noted in more areas treated with 10% urea lotion than those treated with vehicle (79 versus 62 percent).</p><p></p><p class="headingAnchor" id="H59464440"><span class="h3">Topical and systemic retinoids</span><span class="headingEndMark"> — </span>Patients with more severe forms of XLI may benefit from intermittent courses of topical retinoids (eg, <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">tazarotene</a>) or oral retinoids (eg, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>) [<a href="#rid70">70</a>]. Retinoids have antikeratinizing properties and modulate keratinocyte proliferation and differentiation. In children, treatment with topical retinoids is useful and typically individualized according to severity and body surface area involvement. For example, they can be applied to areas of thickest scale, starting once weekly and increasing frequency as tolerated.</p><p>The dosing and administration of topical and systemic retinoids in patients with severe ichthyosis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/128456.html" rel="external">"Inherited ichthyosis: Overview of management", section on 'Topical retinoids'</a> and  <a class="medical medical_review" href="/z/d/html/128456.html" rel="external">"Inherited ichthyosis: Overview of management", section on 'Systemic retinoids'</a>.)</p><p>Retinoic acid metabolism-blocking agents, such as liarozole and rambazole, are an alternative to topical or systemic retinoids. Liarozole has received the orphan drug status by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of congenital ichthyosis, but it is not yet available.</p><p>Evidence on the efficacy of topical or systemic retinoids or retinoic acid metabolism blockers in XLI is limited to a few small, uncontrolled studies; single case reports; and one randomized trial [<a href="#rid71">71-74</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one right-left comparison study, 12 patients with congenital ichthyosis (4 with XLI) applied <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">tazarotene</a> 0.05% gel on one side of the body (≤10 percent of the body surface area) and an ointment containing 10% urea on the contralateral area twice daily for two weeks and then twice weekly for two additional weeks [<a href="#rid71">71</a>]. In the four patients with recessive XLI, a marked clinical improvement was noted only on the side treated with tazarotene after 14 to 20 days, and the beneficial effect persisted for up to two months after discontinuing tazarotene. Adverse effects of tazarotene were mild irritation and discomfort that did not require the interruption of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small, right-left comparison trial, liarozole 5% cream was more effective than vehicle in reducing scaling and roughness in 12 patients with recessive XLI, epidermolytic ichthyosis, or lamellar ichthyosis [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 32 patients (21 with XLI), oral liarozole 150 mg per day was as effective as oral <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> 35 mg per day in inducing a marked improvement in scaling and erythema as assessed by clinician evaluation and patient self-evaluation [<a href="#rid74">74</a>]. Adverse events were moderate and less frequent in the liarozole group.</p><p></p><p>Adverse effects of systemic retinoids include mucosal dryness, photosensitivity, hyperlipidemia, transaminase elevation, and skeletal hyperostosis. As XLI only affects males, the risk of teratogenicity associated with systemic retinoids is not a concern.</p><p class="headingAnchor" id="H98140712"><span class="h2">Management of extracutaneous manifestations</span><span class="headingEndMark"> — </span>Patients with extracutaneous manifestations and patients with contiguous gene syndromes may require a specialized or multidisciplinary approach:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Corneal opacities</strong> – The corneal punctate opacities in XLI are asymptomatic and generally do not cause harm. A baseline ophthalmology examination using a slit lamp to examine the cornea can be considered to document the presence or absence of corneal changes associated with XLI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryptorchidism</strong> – The management of cryptorchidism is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2850.html" rel="external">"Undescended testes (cryptorchidism) in children: Clinical features and evaluation"</a>.)</p><p></p><p class="bulletIndent1">Of particular concern to patients and families is a possible association of XLI with testicular germ cell cancer [<a href="#rid42">42,75</a>]. The data to support a true connection are weak [<a href="#rid19">19</a>]. Because the evidence for a true association of XLI with testicular cancer is weak outside the setting of cryptorchidism, no additional screening measures are recommended for patients without a history of cryptorchidism. (See  <a class="medical medical_review" href="/z/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive/behavioral issues </strong>– The management of attention deficit hyperactivity disorder (ADHD) in children and adolescents is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contiguous gene syndromes</strong> – The management of children with contiguous gene syndromes who present with developmental, endocrine, or neurologic abnormalities and/or intellectual disability requires a multidisciplinary team, including a pediatrician, pediatric neurologist, geneticist, and occupational and physical therapists.</p><p></p><p class="headingAnchor" id="H98140742"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>Patients diagnosed with recessive XLI may benefit from genetics consultation to better understand the inheritance pattern and impact on relatives.</p><p class="bulletIndent1"><span class="glyph">●</span>Mothers who are carriers of steroid sulfatase (STS) deficiency will pass the X chromosome bearing the <em>STS</em> deletion or mutation to 50 percent of offspring. Therefore, 50 percent of male children will be affected by recessive XLI, and 50 percent of female children will be carriers  (<a class="graphic graphic_figure graphicRef55180" href="/z/d/graphic/55180.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Affected fathers will never transmit the disease to their male children, but all female children will be carriers. (See  <a class="medical medical_review" href="/z/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Sex-linked patterns'</a>.)</p><p></p><p>Rare affected females usually have homozygous mutations on both X chromosomes due to consanguinity [<a href="#rid38">38,76</a>].</p><p class="headingAnchor" id="H98140748"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>In the absence of a contiguous gene syndrome,<strong> </strong>the prognosis for patients with recessive XLI is excellent. There is no known reduction in life expectancy associated with XLI [<a href="#rid1">1</a>].</p><p>Scheduled dermatologic follow-up (eg, every six weeks) is initially recommended in patients with XLI to monitor improvement in skin dryness and scaling. Once optimal management is established, "as needed" periodic follow-up is usually sufficient.</p><p class="headingAnchor" id="H3445943442"><span class="h1">ONLINE RESOURCES</span><span class="headingEndMark"> — </span>Information and support for patients and families with recessive XLI can be found on the website of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=15472" target="_blank">Foundation for Ichthyosis and Related Skin Types (FIRST)</a>.</p><p class="headingAnchor" id="H2318610049"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/129484.html" rel="external">"Society guideline links: Ichthyosis"</a>.)</p><p class="headingAnchor" id="H98140760"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – Recessive X-linked ichthyosis (XLI; MIM #308100), also called steroid sulfatase (STS) deficiency, is an X-linked recessive, nonsyndromic ichthyosis caused by deletions or mutations in the <em>STS</em> gene, encoding the STS enzyme. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous features</strong> – The cutaneous features of recessive XLI may appear in the first few weeks of life with mild, diffuse scaling  (<a class="graphic graphic_picture graphicRef103928 graphicRef103927 graphicRef103929 graphicRef103930" href="/z/d/graphic/103928.html" rel="external">picture 1A-D</a>) and gradually develop over the following months. Over time, the mild desquamation may be replaced by large, polygonal, brownish scales that particularly involve the anterior aspect of the lower extremities  (<a class="graphic graphic_picture graphicRef66723 graphicRef90658" href="/z/d/graphic/66723.html" rel="external">picture 2A-B</a>). The flexural areas tend to be spared. (See <a class="local">'Cutaneous features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracutaneous features</strong> – Extracutaneous features include asymptomatic punctate corneal opacities, cryptorchidism, and cognitive/behavioral disorders, especially attention deficit hyperactivity disorder (ADHD). Deletions of the <em>STS</em> gene and adjacent genes result in complicated clinical phenotypes called contiguous gene syndromes. (See <a class="local">'Extracutaneous features'</a> above and <a class="local">'Contiguous gene syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of recessive XLI can be confirmed by biochemical techniques demonstrating absent STS enzyme activity in cultured fibroblasts or by molecular techniques demonstrating a deletion or point mutation of the <em>STS</em> gene. Chromosomal microarray (CMA) may be used to exclude an associated contiguous gene syndrome. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There is no definitive cure for recessive XLI. Symptomatic treatment is directed at removing scales, reducing skin dryness, and improving skin appearance without causing excessive irritation. For most patients with mild to moderate XLI, we suggest regular bathing and use of emollients and keratolytics rather than topical or systemic retinoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical keratolytics should <strong>not</strong> be used in infants and young children because of the high risk of toxicity due to systemic absorption. Patients with severe disease may benefit from intermittent use of topical or systemic retinoids. The management of extracutaneous manifestations may require a specialized or multidisciplinary approach. (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fernandes NF, Janniger CK, Schwartz RA. X-linked ichthyosis: an oculocutaneous genodermatosis. J Am Acad Dermatol 2010; 62:480.</a></li><li><a class="nounderline abstract_t">Craig WY, Roberson M, Palomaki GE, et al. Prevalence of steroid sulfatase deficiency in California according to race and ethnicity. Prenat Diagn 2010; 30:893.</a></li><li><a class="nounderline abstract_t">Sakura N, Nishimura SI, Matsumoto T, Ohsaki M. Frequency of steroid sulfatase deficiency in Hiroshima. Acta Paediatr Jpn 1998; 40:63.</a></li><li><a class="nounderline abstract_t">David M, Israel N, Merksamer R, et al. Very low maternal serum unconjugated estriol and prenatal diagnosis of steroid sulfatase deficiency. Fetal Diagn Ther 1995; 10:76.</a></li><li><a class="nounderline abstract_t">Ingordo V, D'Andria G, Gentile C, et al. Frequency of X-linked ichthyosis in coastal southern Italy: a study on a representative sample of a young male population. Dermatology 2003; 207:148.</a></li><li><a class="nounderline abstract_t">Cavenagh A, Chatterjee S, Davies W. Behavioural and psychiatric phenotypes in female carriers of genetic mutations associated with X-linked ichthyosis. PLoS One 2019; 14:e0212330.</a></li><li><a class="nounderline abstract_t">Cañueto J, Ciria S, Hernández-Martín A, et al. Analysis of the STS gene in 40 patients with recessive X-linked ichthyosis: a high frequency of partial deletions in a Spanish population. J Eur Acad Dermatol Venereol 2010; 24:1226.</a></li><li><a class="nounderline abstract_t">Ballabio A, Carrozzo R, Parenti G, et al. Molecular heterogeneity of steroid sulfatase deficiency: a multicenter study on 57 unrelated patients, at DNA and protein levels. Genomics 1989; 4:36.</a></li><li><a class="nounderline abstract_t">Oyama N, Matsuda M, Hamada T, et al. Two novel missense mutations of STS gene underlie X-linked recessive ichthyosis: understanding of the mutational and structural spectrum. J Eur Acad Dermatol Venereol 2016; 30:1629.</a></li><li><a class="nounderline abstract_t">Alperin ES, Shapiro LJ. Characterization of point mutations in patients with X-linked ichthyosis. Effects on the structure and function of the steroid sulfatase protein. J Biol Chem 1997; 272:20756.</a></li><li><a class="nounderline abstract_t">Nagtzaam IF, van Leersum FS, Kouwenberg LCM, et al. STS pathogenic variants in a Dutch patient cohort clinically suspected for X-linked ichthyosis show genetic heterogeneity. Br J Dermatol 2022; 187:820.</a></li><li><a class="nounderline abstract_t">Happle R. X-chromosome inactivation: role in skin disease expression. Acta Paediatr Suppl 2006; 95:16.</a></li><li><a class="nounderline abstract_t">Wang JC, Passage MB, Ellison J, et al. Physical mapping of loci in the distal half of the short arm of the human X chromosome: implications for the spreading of X-chromosome inactivation. Somat Cell Mol Genet 1992; 18:195.</a></li><li><a class="nounderline abstract_t">Valdes-Flores M, Kofman-Alfaro SH, Jimenez-Vaca AL, Cuevas-Covarrubias SA. Carrier identification by FISH analysis in isolated cases of X-linked ichthyosis. Am J Med Genet 2001; 102:146.</a></li><li><a class="nounderline abstract_t">Cuevas-Covarrubias SA, Valdes-Flores M, Orozco Orozco E, et al. Most "sporadic" cases of X-linked ichthyosis are not de novo mutations. Acta Derm Venereol 1999; 79:143.</a></li><li><a class="nounderline abstract_t">Langlois S, Armstrong L, Gall K, et al. Steroid sulfatase deficiency and contiguous gene deletion syndrome amongst pregnant patients with low serum unconjugated estriols. Prenat Diagn 2009; 29:966.</a></li><li><a class="nounderline abstract_t">Chocholska S, Rossier E, Barbi G, Kehrer-Sawatzki H. Molecular cytogenetic analysis of a familial interstitial deletion Xp22.2-22.3 with a highly variable phenotype in female carriers. Am J Med Genet A 2006; 140:604.</a></li><li><a class="nounderline abstract_t">Süßmuth K, Gruber R, Rodriguez E, et al. Increased Prevalence of Filaggrin Deficiency in 51 Patients with Recessive X-Linked Ichthyosis Presenting for Dermatological Examination. J Invest Dermatol 2018; 138:709.</a></li><li><a class="nounderline abstract_t">Elias PM, Williams ML, Choi EH, Feingold KR. Role of cholesterol sulfate in epidermal structure and function: lessons from X-linked ichthyosis. Biochim Biophys Acta 2014; 1841:353.</a></li><li><a class="nounderline abstract_t">Reed MJ, Purohit A, Woo LW, et al. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 2005; 26:171.</a></li><li><a class="nounderline abstract_t">Rodrigo-Nicolás B, Bueno-Martínez E, Martín-Santiago A, et al. Evidence of the high prevalence of neurological disorders in nonsyndromic X-linked recessive ichthyosis: a retrospective case series. Br J Dermatol 2018; 179:933.</a></li><li><a class="nounderline abstract_t">Elias PM, Williams ML, Maloney ME, et al. Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal desquamation and the pathogenesis of recessive X-linked ichthyosis. J Clin Invest 1984; 74:1414.</a></li><li><a class="nounderline abstract_t">Sato J, Denda M, Nakanishi J, et al. Cholesterol sulfate inhibits proteases that are involved in desquamation of stratum corneum. J Invest Dermatol 1998; 111:189.</a></li><li><a class="nounderline abstract_t">Zettersten E, Man MQ, Sato J, et al. Recessive x-linked ichthyosis: role of cholesterol-sulfate accumulation in the barrier abnormality. J Invest Dermatol 1998; 111:784.</a></li><li><a class="nounderline abstract_t">Traupe H. Revealing the mysteries of X-linked recessive ichthyosis. Br J Dermatol 2018; 179:821.</a></li><li><a class="nounderline abstract_t">Brcic L, Underwood JF, Kendall KM, et al. Medical and neurobehavioural phenotypes in carriers of X-linked ichthyosis-associated genetic deletions in the UK Biobank. J Med Genet 2020; 57:692.</a></li><li><a class="nounderline abstract_t">Bradley LA, Canick JA, Palomaki GE, Haddow JE. Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. Am J Obstet Gynecol 1997; 176:531.</a></li><li><a class="nounderline abstract_t">Jari SD, Fraer LM, Hogge WA. Association of undetectable unconjugated estriol on multiple marker screening with steroid sulfatase deficiency. Fetal Diagn Ther 2004; 19:43.</a></li><li><a class="nounderline abstract_t">Bedin M, Fournier T, Cabrol D, et al. Incidence of placental sulfatase deficiency on the mode of termination of pregnancy. Gynecol Obstet Invest 1987; 24:86.</a></li><li><a class="nounderline abstract_t">Kent L, Emerton J, Bhadravathi V, et al. X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits. J Med Genet 2008; 45:519.</a></li><li><a class="nounderline abstract_t">Brookes KJ, Hawi Z, Kirley A, et al. Association of the steroid sulfatase (STS) gene with attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1531.</a></li><li><a class="nounderline abstract_t">Diociaiuti A, Angioni A, Pisaneschi E, et al. X-linked ichthyosis: Clinical and molecular findings in 35 Italian patients. Exp Dermatol 2019; 28:1156.</a></li><li><a class="nounderline abstract_t">Hernández-Martín A, González-Sarmiento R, De Unamuno P. X-linked ichthyosis: an update. Br J Dermatol 1999; 141:617.</a></li><li><a class="nounderline abstract_t">Ramesh R, Chen H, Kukula A, et al. Exacerbation of X-linked ichthyosis phenotype in a female by inheritance of filaggrin and steroid sulfatase mutations. J Dermatol Sci 2011; 64:159.</a></li><li><a class="nounderline abstract_t">Liao H, Waters AJ, Goudie DR, et al. Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis. J Invest Dermatol 2007; 127:2795.</a></li><li><a class="nounderline abstract_t">Cuevas-Covarrubias SA, Valdes-Flores M, Rivera-Vega MR, et al. Ichthyosis vulgaris and X-linked ichthyosis: simultaneous segregation in the same family. Acta Derm Venereol 1999; 79:494.</a></li><li><a class="nounderline abstract_t">De Palma AM, Mazereeuw-Hautier J, Giehl K, et al. Burden of itch in ichthyosis: a multicentre study in 94 patients. J Eur Acad Dermatol Venereol 2019; 33:2095.</a></li><li><a class="nounderline abstract_t">Afzal S, Ramzan K, Ullah S, et al. A novel nonsense mutation in the STS gene in a Pakistani family with X-linked recessive ichthyosis: including a very rare case of two homozygous female patients. BMC Med Genet 2020; 21:20.</a></li><li><a class="nounderline abstract_t">Hung C, Ayabe RI, Wang C, et al. Pre-Descemet corneal dystrophy and X-linked ichthyosis associated with deletion of Xp22.31 containing the STS gene. Cornea 2013; 32:1283.</a></li><li><a class="nounderline abstract_t">Shi H, Qi XF, Liu TT, et al. In vivo confocal microscopy of pre-Descemet corneal dystrophy associated with X-linked ichthyosis: a case report. BMC Ophthalmol 2017; 17:29.</a></li><li><a class="nounderline abstract_t">Boere PM, Bonnet C, Frausto RF, et al. Multimodal Imaging of Pre-Descemet Corneal Dystrophy Associated With X-Linked Ichthyosis and Deletion of the STS Gene. Cornea 2020; 39:1442.</a></li><li><a class="nounderline abstract_t">Lykkesfeldt G, Bennett P, Lykkesfeldt AE, et al. Testis cancer. Ichthyosis constitutes a significant risk factor. Cancer 1991; 67:730.</a></li><li><a class="nounderline abstract_t">Lykkesfeldt G, Høyer H, Lykkesfeldt AE, Skakkebaek NE. Steroid sulphatase deficiency associated with testis cancer. Lancet 1983; 2:1456.</a></li><li><a class="nounderline abstract_t">Mishra K, Batra VV, Basu S, et al. Steroid-resistant nephrotic syndrome associated with steroid sulfatase deficiency-x-linked recessive ichthyosis: a case report and review of literature. Eur J Pediatr 2012; 171:847.</a></li><li><a class="nounderline abstract_t">Krishnamurthy S, Kapoor S, Yadav S. Nephrotic syndrome with X-linked ichthyosis, Kallmann Syndrome and unilateral renal agenesis. Indian Pediatr 2007; 44:301.</a></li><li><a class="nounderline abstract_t">Matsukura H, Fuchizawa T, Ohtsuki A, et al. End-stage renal failure in a child with X-linked ichthyosis. Pediatr Nephrol 2003; 18:297.</a></li><li><a class="nounderline abstract_t">Song Y, Chen J, Yi Z, et al. Genetic analysis of a 12-year-old boy with X-linked ichthyosis in association with sclerosing glomerulonephritis. Mol Med Rep 2013; 8:1183.</a></li><li><a class="nounderline abstract_t">Wren GH, Humby T, Thompson AR, Davies W. Mood symptoms, neurodevelopmental traits, and their contributory factors in X-linked ichthyosis, ichthyosis vulgaris and psoriasis. Clin Exp Dermatol 2022; 47:1097.</a></li><li><a class="nounderline abstract_t">Myers KA, Simard-Tremblay E, Saint-Martin C. X-Linked Familial Focal Epilepsy Associated With Xp22.31 Deletion. Pediatr Neurol 2020; 108:113.</a></li><li><a class="nounderline abstract_t">Ballabio A, Bardoni B, Carrozzo R, et al. Contiguous gene syndromes due to deletions in the distal short arm of the human X chromosome. Proc Natl Acad Sci U S A 1989; 86:10001.</a></li><li><a class="nounderline abstract_t">Van Esch H, Hollanders K, Badisco L, et al. Deletion of VCX-A due to NAHR plays a major role in the occurrence of mental retardation in patients with X-linked ichthyosis. Hum Mol Genet 2005; 14:1795.</a></li><li><a class="nounderline abstract_t">Ozawa H, Osawa M, Nagai T, Sakura N. Steroid sulfatase deficiency with bilateral periventricular nodular heterotopia. Pediatr Neurol 2006; 34:239.</a></li><li><a class="nounderline abstract_t">Ballabio A, Parenti G, Tippett P, et al. X-linked ichthyosis, due to steroid sulphatase deficiency, associated with Kallmann syndrome (hypogonadotropic hypogonadism and anosmia): linkage relationships with Xg and cloned DNA sequences from the distal short arm of the X chromosome. Hum Genet 1986; 72:237.</a></li><li><a class="nounderline abstract_t">Curry CJ, Magenis RE, Brown M, et al. Inherited chondrodysplasia punctata due to a deletion of the terminal short arm of an X chromosome. N Engl J Med 1984; 311:1010.</a></li><li><a class="nounderline abstract_t">Bick DP, Schorderet DF, Price PA, et al. Prenatal diagnosis and investigation of a fetus with chondrodysplasia punctata, ichthyosis, and Kallmann syndrome due to an Xp deletion. Prenat Diagn 1992; 12:19.</a></li><li><a class="nounderline abstract_t">Ballabio A, Parenti G, Carrozzo R, et al. X/Y translocation in a family with X-linked ichthyosis, chondrodysplasia punctata, and mental retardation: DNA analysis reveals deletion of the steroid sulphatase gene and translocation of its Y pseudogene. Clin Genet 1988; 34:31.</a></li><li><a class="nounderline abstract_t">Ross JB, Allderdice PW, Shapiro LJ, et al. Familial X-linked ichthyosis, steroid sulfatase deficiency, mental retardation, and nullisomy for Xp223-pter. Arch Dermatol 1985; 121:1524.</a></li><li><a class="nounderline abstract_t">Sunohara N, Sakuragawa N, Satoyoshi E, et al. A new syndrome of anosmia, ichthyosis, hypogonadism, and various neurological manifestations with deficiency of steroid sulfatase and arylsulfatase C. Ann Neurol 1986; 19:174.</a></li><li><a class="nounderline abstract_t">Hand JL, Runke CK, Hodge JC. The phenotype spectrum of X-linked ichthyosis identified by chromosomal microarray. J Am Acad Dermatol 2015; 72:617.</a></li><li><a class="nounderline abstract_t">Yang CS, Pomerantz H, Mannava KA, et al. Comparing histopathology from patients with X-linked recessive ichthyosis and autosomal recessive congenital ichthyosis with transglutaminase 1 mutation: A report from the National Registry for Ichthyosis and Related Skin Disorders. J Am Acad Dermatol 2016; 74:1008.</a></li><li><a class="nounderline abstract_t">Gånemo A, Sjöden PO, Johansson E, et al. Health-related quality of life among patients with ichthyosis. Eur J Dermatol 2004; 14:61.</a></li><li><a class="nounderline abstract_t">Dreyfus I, Pauwels C, Bourrat E, et al. Burden of inherited ichthyosis: a French national survey. Acta Derm Venereol 2015; 95:326.</a></li><li><a class="nounderline abstract_t">Gånemo A. Quality of life in Swedish children with congenital ichthyosis. Dermatol Reports 2010; 2:e7.</a></li><li><a class="nounderline abstract_t">Vahlquist A, Gånemo A, Virtanen M. Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol 2008; 88:4.</a></li><li><a class="nounderline abstract_t">Milstone LM. Scaly skin and bath pH: rediscovering baking soda. J Am Acad Dermatol 2010; 62:885.</a></li><li><a class="nounderline abstract_t">Ramírez ME, Youseef WF, Romero RG, et al. Acute percutaneous lactic acid poisoning in a child. Pediatr Dermatol 2006; 23:282.</a></li><li><a class="nounderline abstract_t">Brubacher JR, Hoffman RS. Salicylism from topical salicylates: review of the literature. J Toxicol Clin Toxicol 1996; 34:431.</a></li><li><a class="nounderline abstract_t">Chiaretti A, Schembri Wismayer D, Tortorolo L, et al. Salicylate intoxication using a skin ointment. Acta Paediatr 1997; 86:330.</a></li><li><a class="nounderline abstract_t">Küster W, Bohnsack K, Rippke F, et al. Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology 1998; 196:217.</a></li><li><a class="nounderline abstract_t">Zaenglein AL, Levy ML, Stefanko NS, et al. Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatr Dermatol 2021; 38:164.</a></li><li><a class="nounderline abstract_t">Hofmann B, Stege H, Ruzicka T, Lehmann P. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999; 141:642.</a></li><li><a class="nounderline abstract_t">Cotellessa C, Cuevas-Covarrubias SA, Valeri P, et al. Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene. Acta Derm Venereol 2005; 85:346.</a></li><li><a class="nounderline abstract_t">Lucker GP, Verfaille CJ, Heremans AM, et al. Topical liarozole in ichthyosis: a double-blind, left-right comparative study followed by a long-term open maintenance study. Br J Dermatol 2005; 152:566.</a></li><li><a class="nounderline abstract_t">Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C, et al. Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study. Br J Dermatol 2007; 156:965.</a></li><li><a class="nounderline abstract_t">Lykkesfeldt G, Høyer H. Topical cholesterol treatment of recessive X-linked ichthyosis. Lancet 1983; 2:1337.</a></li><li><a class="nounderline abstract_t">Diociaiuti A, Angioni A, Pisaneschi E, et al. Next Generation Sequencing Uncovers a Rare Case of X-linked Ichthyosis in an Adopted Girl Homozygous for a Novel Nonsense Mutation in the STS Gene. Acta Derm Venereol 2019; 99:828.</a></li></ol></div><div id="topicVersionRevision">Topic 15472 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20080321" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : X-linked ichthyosis: an oculocutaneous genodermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20715120" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of steroid sulfatase deficiency in California according to race and ethnicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9583203" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Frequency of steroid sulfatase deficiency in Hiroshima.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7794518" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Very low maternal serum unconjugated estriol and prenatal diagnosis of steroid sulfatase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920363" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Frequency of X-linked ichthyosis in coastal southern Italy: a study on a representative sample of a young male population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30768640" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Behavioural and psychiatric phenotypes in female carriers of genetic mutations associated with X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20236202" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Analysis of the STS gene in 40 patients with recessive X-linked ichthyosis: a high frequency of partial deletions in a Spanish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644167" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular heterogeneity of steroid sulfatase deficiency: a multicenter study on 57 unrelated patients, at DNA and protein levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26387488" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Two novel missense mutations of STS gene underlie X-linked recessive ichthyosis: understanding of the mutational and structural spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9252398" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characterization of point mutations in patients with X-linked ichthyosis. Effects on the structure and function of the steroid sulfatase protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35822528" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : STS pathogenic variants in a Dutch patient cohort clinically suspected for X-linked ichthyosis show genetic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16720460" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : X-chromosome inactivation: role in skin disease expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1315458" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Physical mapping of loci in the distal half of the short arm of the human X chromosome: implications for the spreading of X-chromosome inactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477606" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Carrier identification by FISH analysis in isolated cases of X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228635" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Most "sporadic" cases of X-linked ichthyosis are not de novo mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19609942" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Steroid sulfatase deficiency and contiguous gene deletion syndrome amongst pregnant patients with low serum unconjugated estriols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470742" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Molecular cytogenetic analysis of a familial interstitial deletion Xp22.2-22.3 with a highly variable phenotype in female carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054605" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increased Prevalence of Filaggrin Deficiency in 51 Patients with Recessive X-Linked Ichthyosis Presenting for Dermatological Examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24291327" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Role of cholesterol sulfate in epidermal structure and function: lessons from X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561802" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Steroid sulfatase: molecular biology, regulation, and inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29901853" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evidence of the high prevalence of neurological disorders in nonsyndromic X-linked recessive ichthyosis: a retrospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6592175" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal desquamation and the pathogenesis of recessive X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9699715" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cholesterol sulfate inhibits proteases that are involved in desquamation of stratum corneum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9804339" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recessive x-linked ichthyosis: role of cholesterol-sulfate accumulation in the barrier abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30318799" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Revealing the mysteries of X-linked recessive ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139392" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Medical and neurobehavioural phenotypes in carriers of X-linked ichthyosis-associated genetic deletions in the UK Biobank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9077601" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14646417" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Association of undetectable unconjugated estriol on multiple marker screening with steroid sulfatase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3477518" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incidence of placental sulfatase deficiency on the mode of termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413370" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937300" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of the steroid sulfatase (STS) gene with attention deficit hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29672931" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : X-linked ichthyosis: Clinical and molecular findings in 35 Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583107" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : X-linked ichthyosis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21945601" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Exacerbation of X-linked ichthyosis phenotype in a female by inheritance of filaggrin and steroid sulfatase mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17657246" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10598781" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ichthyosis vulgaris and X-linked ichthyosis: simultaneous segregation in the same family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31062435" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Burden of itch in ichthyosis: a multicentre study in 94 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32005174" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A novel nonsense mutation in the STS gene in a Pakistani family with X-linked recessive ichthyosis: including a very rare case of two homozygous female patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23807007" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pre-Descemet corneal dystrophy and X-linked ichthyosis associated with deletion of Xp22.31 containing the STS gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28302098" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : In vivo confocal microscopy of pre-Descemet corneal dystrophy associated with X-linked ichthyosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32482962" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Multimodal Imaging of Pre-Descemet Corneal Dystrophy Associated With X-Linked Ichthyosis and Deletion of the STS Gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898710" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Testis cancer. Ichthyosis constitutes a significant risk factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6140547" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Steroid sulphatase deficiency associated with testis cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419362" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Steroid-resistant nephrotic syndrome associated with steroid sulfatase deficiency-x-linked recessive ichthyosis: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17468528" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nephrotic syndrome with X-linked ichthyosis, Kallmann Syndrome and unilateral renal agenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12644929" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : End-stage renal failure in a child with X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23939749" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Genetic analysis of a 12-year-old boy with X-linked ichthyosis in association with sclerosing glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35104372" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mood symptoms, neurodevelopmental traits, and their contributory factors in X-linked ichthyosis, ichthyosis vulgaris and psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32299744" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : X-Linked Familial Focal Epilepsy Associated With Xp22.31 Deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2602357" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Contiguous gene syndromes due to deletions in the distal short arm of the human X chromosome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888481" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Deletion of VCX-A due to NAHR plays a major role in the occurrence of mental retardation in patients with X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16504797" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Steroid sulfatase deficiency with bilateral periventricular nodular heterotopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3007328" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : X-linked ichthyosis, due to steroid sulphatase deficiency, associated with Kallmann syndrome (hypogonadotropic hypogonadism and anosmia): linkage relationships with Xg and cloned DNA sequences from the distal short arm of the X chromosome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6482910" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Inherited chondrodysplasia punctata due to a deletion of the terminal short arm of an X chromosome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1557308" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prenatal diagnosis and investigation of a fetus with chondrodysplasia punctata, ichthyosis, and Kallmann syndrome due to an Xp deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3165728" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : X/Y translocation in a family with X-linked ichthyosis, chondrodysplasia punctata, and mental retardation: DNA analysis reveals deletion of the steroid sulphatase gene and translocation of its Y pseudogene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3864397" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Familial X-linked ichthyosis, steroid sulfatase deficiency, mental retardation, and nullisomy for Xp223-pter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516063" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A new syndrome of anosmia, ichthyosis, hypogonadism, and various neurological manifestations with deficiency of steroid sulfatase and arylsulfatase C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25659225" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The phenotype spectrum of X-linked ichthyosis identified by chromosomal microarray.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27085231" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparing histopathology from patients with X-linked recessive ichthyosis and autosomal recessive congenital ichthyosis with transglutaminase 1 mutation: A report from the National Registry for Ichthyosis and Related Skin Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14965800" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Health-related quality of life among patients with ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25510955" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Burden of inherited ichthyosis: a French national survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25386243" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Quality of life in Swedish children with congenital ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18176742" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Congenital ichthyosis: an overview of current and emerging therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20398816" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Scaly skin and bath pH: rediscovering baking soda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16780481" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Acute percutaneous lactic acid poisoning in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8699558" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Salicylism from topical salicylates: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9099329" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Salicylate intoxication using a skin ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9568411" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33169909" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583110" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of topical tazarotene in the treatment of congenital ichthyoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16191859" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787831" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Topical liarozole in ichthyosis: a double-blind, left-right comparative study followed by a long-term open maintenance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17263800" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6139672" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Topical cholesterol treatment of recessive X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30834456" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Next Generation Sequencing Uncovers a Rare Case of X-linked Ichthyosis in an Adopted Girl Homozygous for a Novel Nonsense Mutation in the STS Gene.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
